Evidence-based·Updated November 19, 2026·How we grade evidence

AOD-9604

PeptideResearch peptide

AOD-9604 failed as an obesity drug: in the company's largest trial, oral doses for 24 weeks did not cause significant weight loss versus placebo, and development ended in 2007. FDA reviewed it in 2024 and found a lack of evidence of effectiveness for obesity by any route and insufficient safety information, and its advisory committee voted 12 to 0 against allowing it in pharmacy compounding. Claims about cartilage, joints, bones or anti-aging rest on animal or no data.

Taking AOD-9604 with other supplements or medications?Check your whole list for interactions. Free, no account.

Research compound: not an approved drug or dietary supplement

This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only. Talk to a clinician before considering it.

Quick decision guide

May help most

No approved or proven use

Common dosing range

No approved or established dose. Company trials, as summarized by FDA, tested oral doses of 0.25 to 30 mg a day for up to 24 weeks (higher doses only in short studies); FDA found no human data for injections under the skin, the form sold today

When to expect effects

No meaningful effect shown in people

Watch out for

Not FDA-approved; failed its obesity trials; FDA found limited safety data, no human data for injections, and cancer reports in one trial it could not resolve; it is on WADA's prohibited list according to FDA's review; online and clinic products are unverified

What is it

AOD-9604 is a lab-made peptide based on the tail end of human growth hormone (amino acids 177 to 191, with an extra tyrosine added). The Australian company Metabolic Pharmaceuticals developed it in the late 1990s as a pill for obesity, and stopped in February 2007 after its largest trial (502 randomized adults with obesity, 24 weeks) did not show significant weight loss compared with placebo. It is not FDA-approved, and FDA's 2024 review found no monograph for it in the major pharmacopeias of Europe, China, India or Japan. On December 4, 2024, after FDA proposed that it not be included, FDA's Pharmacy Compounding Advisory Committee voted 0 yes and 12 no on placing AOD-9604 on the list of bulk substances pharmacies may use in compounding under section 503A, and FDA now lists it among substances once in category 2 (may present significant safety risks) whose nominations were withdrawn. It is still marketed by clinics, med spas and online sellers, mostly as injections, a route FDA found no human data for.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You want to lose weight and are willing to discuss FDA-approved obesity medicines and lifestyle programs with a doctor instead, as FDA's review points out such options exist

Probably skip if…

You want weight loss: the company's largest trial did not show significant weight loss versus placebo, and FDA found a lack of evidence of effectiveness for obesity
You want it for joint, cartilage or bone repair: there are no human studies for these uses
You would be buying injections, capsules or melts from a clinic, med spa or website: no product is approved, and FDA found no human data for injection
You compete in sport under anti-doping rules: FDA's review notes it is on WADA's prohibited list

Evidence at a glance

fat breakdown and weight gain in obese mice and rats

Mixed Evidence
Effect
Weight gain cut by more than half in obese rats; no significant weight loss in human trials
Best fit
None in people
Time
2 to 3 weeks in rodents

cartilage repair in a rabbit model of knee osteoarthritis

Mixed Evidence
Effect
Better cartilage scores than saline in rabbits
Best fit
None in people
Time
Measured at 8 weeks in rabbits

Evidence for 2 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

fat breakdown and weight gain in obese mice and rats

Mechanism only
Mixed Evidence

In obese mice given AOD-9604 by pump for 14 days, weight gain was lower, fat burning and fat breakdown increased, and, unlike full growth hormone, blood sugar did not rise; AOD-9604 did not bind the growth hormone receptor. In obese Zucker rats, a daily oral dose of 500 micrograms per kg for 19 days cut weight gain by more than half (15.8 versus 35.6 g). These are animal results and have not been shown in people. Separately, FDA's 2024 briefing document for its Pharmacy Compounding Advisory Committee reports that in most of the human studies it identified, AOD-9604 did not beat placebo for weight loss, including the largest trial (502 randomized adults with obesity, 24 weeks, with diet and exercise), which missed its primary endpoint at 12 weeks.

Effect size
Weight gain cut by more than half in obese rats; no significant weight loss in human trials
Time to effect
2 to 3 weeks in rodents
Best fit
None in people
Less likely
People with obesity, in whom weight loss was not shown

Bottom line: It slowed weight gain in rodents, but failed to cause meaningful weight loss in human trials.

cartilage repair in a rabbit model of knee osteoarthritis

Mechanism only
Mixed Evidence

In 32 rabbits with knee damage induced by an enzyme, weekly injections of AOD-9604 into the knee (weeks 4 to 7) led to better cartilage scores and shorter lameness than saline, and the combination with hyaluronic acid did better than either alone. This has never been tested in people: FDA's 2024 review found no clinical studies of AOD-9604 for osteoarthritis or osteoporosis, and the rabbit study used injections into the joint, not the under-the-skin injections sellers promote.

Effect size
Better cartilage scores than saline in rabbits
Time to effect
Measured at 8 weeks in rabbits
Best fit
None in people
Less likely
People with joint pain or osteoarthritis, who have not been studied

Bottom line: A single rabbit study; there is no human evidence for joints or cartilage.

How it works

In obese mice and rats, AOD-9604 increased fat breakdown and fat burning and slowed weight gain without raising blood sugar, which full growth hormone does. It did not bind the growth hormone receptor or make cells multiply, so it is not a form of growth hormone and is not expected to raise IGF-1; in the company's human trials, IGF-1 did not change. FDA's review says its actual molecular target and mechanism remain unknown. In small human studies summarized by FDA, single intravenous or oral doses briefly raised blood free fatty acids, a sign of fat breakdown, but that did not translate into meaningful weight loss.

How to take it

1. Typical dose
There is no approved or established dose. According to FDA's 2024 review of the company trials, people with obesity received oral AOD-9604 at 0.25, 0.5 or 1 mg a day for 24 weeks, or 1 to 30 mg a day for 12 weeks, and earlier studies gave single intravenous doses of 25 to 400 micrograms per kg. None of these showed meaningful weight loss, and they are studied doses, not recommendations.
2. Higher studied dose
Oral doses up to 54 mg were given in short studies; men on 54 mg had more headaches, diarrhea and flatulence.
3. Timing
Not established.
4. With food
Not established.
5. Split dosing
Not established.
6. How long to try
Human trials lasted up to 24 weeks, by mouth. FDA found no information on long-term safety, and no human data at all for injections under the skin or creams.

What to track

If you have used it: tell your doctor
Injection-site redness, swelling or signs of infection, a known risk with injected products of unknown quality
Headache, diarrhea, chest tightness or unusual mood changes, which were reported in trials

Bottom line: There is no dose that has been shown to work, and the injected form was never tested in people.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Headache, fatigue and dizziness after intravenous doses in the company's trials (the authors said side effects were similar with placebo)Headache, diarrhea, flatulence, increased appetite and nausea after oral dosesEuphoria (mild to moderate), judged possibly related in one intravenous studyInjection-site reactions are possible with any injected peptide; the form sold today was never tested in people

Serious risks

Who should avoid it

Pregnancy & breastfeeding

There are no human data on AOD-9604 in pregnancy or breastfeeding, and FDA's 2024 review identified no animal studies of its effects on reproduction or development. Avoid use if you are pregnant, breastfeeding or planning a pregnancy, and talk to your doctor.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

There is no FDA-approved AOD-9604 product, so no label can show FDA approval
FDA's advisory committee voted 12 to 0 against placing AOD-9604 on the list of substances pharmacies may compound, and compounded drugs are not FDA-approved, so a "compounded" label does not mean it has been reviewed

Be skeptical of…

"Fat-burning peptide" or "proven weight loss": the company's largest trial found no significant weight loss versus placebo
"Repairs cartilage, joints or bones": only one rabbit study exists; FDA found no human studies
"FDA-approved" AOD-9604: no AOD-9604 product is FDA-approved
"The safe part of growth hormone, no side effects": FDA found limited safety data and unresolved cancer reports in one trial
"Anti-aging", "boosts metabolism" or "muscle-building": none of these has been tested in people
"For research use only" vials, or stacks with BPC-157 and other peptides: unapproved, unverified, and untested in combination

Frequently asked questions

Is AOD-9604 FDA-approved?⌄

No. No AOD-9604 product is approved by FDA. It was developed as an obesity pill in Australia, and development stopped in 2007 after its largest trial did not show significant weight loss.

Does AOD-9604 work for weight loss?⌄

The evidence says no. According to FDA's 2024 review, most of the company's trials did not show weight loss beyond placebo; one 12-week trial, reported only in a meeting abstract, claimed small differences that FDA said have unclear meaningful therapeutic effects. Its largest trial (502 randomized adults with obesity, 24 weeks, with a diet and exercise program) missed its main goal. FDA concluded there is a lack of evidence of effectiveness for obesity by any route. Ask your doctor about approved weight-management options.

Can a compounding pharmacy legally make AOD-9604?⌄

On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 0 yes and 12 no on placing AOD-9604 on the list of bulk substances that pharmacies may use under section 503A, after FDA proposed not adding it. FDA's compounding safety page now lists AOD-9604 among substances previously in category 2 whose nominations were withdrawn. Compounded drugs are not FDA-approved and are not checked by FDA for safety or quality.

Is AOD-9604 the same as growth hormone?⌄

No. It is a small piece of the growth hormone molecule with an added amino acid. In lab studies it did not bind the growth hormone receptor, and in company trials it did not change IGF-1 levels. It does not do what growth hormone does.

Is it banned in sport?⌄

FDA's 2024 review notes that AOD-9604 is on the World Anti-Doping Agency's prohibited list under section S2.2, that an Australian Crime Commission report listed it as supplied to athletes, and that it has been found in vials obtained from elite athletes in Germany and Belgium and in confiscated vials in the US.

Can I take AOD-9604 with my supplements or medicines?⌄

No interaction studies exist, and no human data exist for the injected form that is sold today. Products are often sold in combination with other peptides or drugs, which adds unknown risks. A doctor or pharmacist should review your full list.

References by claim

fat breakdown and weight gain in obese mice and rats

Heffernan et al., 2001 · PubMed (2001) link

Ng et al., 2000 · PubMed (2000) link

cartilage repair in a rabbit model of knee osteoarthritis

Kwon et al., 2015 · PubMed (2015) link

Safety

FDA briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee: AOD-9604-related bulk drug substances · FDA link

FDA: Certain bulk drug substances for use in compounding that may present significant safety risks · FDA link

Track AOD-9604 with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 19, 2026·Evidence current as of Nov 19, 2026·How we grade evidence

Disclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research (much of it preclinical or early-stage), not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.